Immunoprophylaxis against important virus diseases of horses, farm animals and birds

Vaccine

Volumn 27, Issue 12, 2009, Pages 1797-1810

  Patel, J R ^a   Heldens, J G M ^b  

^a JAS Biologicals Limited   (United Kingdom)

^b Nobilon International BV   (Netherlands)

Author keywords

Farm animals; Vaccines; Viruses

Indexed keywords

BOVINE RESPIRATORY DISEASE COMPLEX VACCINE; BOVINE VIRAL DIARRHEA VIRUS VACCINE; DNA VACCINE; FOOT AND MOUTH DISEASE VACCINE; HERPES VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; RABIES VACCINE; RECOMBINANT CYTOKINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

BIOTECHNOLOGY; BIRD; CATTLE DISEASE; CIRCOVIRIDAE; DRUG EFFICACY; DRUG FORMULATION; ENCEPHALOMYELITIS; FARM ANIMAL; FOOT AND MOUTH DISEASE; HERPES VIRUS; HORSE; HORSE DISEASE; IMMUNOPROPHYLAXIS; INFLUENZA; MOLECULAR GENETICS; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; RABIES; REVIEW; STOMATITIS; SWINE DISEASE; SYMPTOMATOLOGY; VESICULAR STOMATITIS; VIRUS INFECTION; VIRUS RECOMBINANT;

ANIMAL DISEASES; ANIMALS; ANIMALS, DOMESTIC; BIRD DISEASES; HORSE DISEASES; HORSES; SHEEP; SHEEP DISEASES; SWINE; SWINE DISEASES; VIRUS DISEASES;

EID: 61349167735     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.063     Document Type: Review

References (144)

1. Reidel S. Edward Jenner and the history of smallpox and vaccination. Baylor University Medical Centre Proceedings 2005;18:21-5.
2. Heldens JGM, Patel JR, Chanter N, ten Thij GJ, Gravendijck M, Schijns VEJC, et al. Veterinary vaccine development from an industrial perspective. The Veterinary Journal 2008;178:7-20.
3. Anonymous. Office international des epizooties. Animal Health Code (1997) 1997
4. Westergaard J.M. Control strategies of major viral infectious diseases of live stock in Europe, ten years of experience. In: Brocchi A., and Lavaza A. (Eds). Proceedings of the 5th international congress of the European society for veterinary virology (2000), Instituto Zooprofillatico Sperimentale della Lombardia e dell Emilia Romagna, Brescia Fondazione Iniziative Zooprofilattiche e Zootechniche, Brescia, Italy 3-12
5. Kitching P., Hammond J., Jeggo M., Charleston B., Paton D., Rodriguez L., et al. Global FMD control-is it an option?. Vaccine 25 (2007) 5660-5664
6. Patel J.R., and Heldens J. Equine herpesvirusus 1 (EHV-1) and 4 (EHV-4)-epidemiology, disease and immunoprophylaxis; a brief review. The Veterinary Journal 170 (2005) 14-23
7. Heldens J.G.M., Hannant D., Cullinane A.A., Prendergast M.J., Mumford M.A., Nelly M., et al. Clinical and virological evaluation of the efficacy of an inactivated EHV1 and EHV4 whole virus vaccine (Duvaxyn EHV1, 4). Vaccination/challenge experiments in foals and pregnant mares. Vaccine 19 (2001) 4307-4317
8. Patel J.R., Bateman H., Williams J., and Didlick S. Derivation and characterisation of a live equid herpesvirus 1 (EHV-1) vaccine to protect against abortion and respiratory disease due to EHV-1. Veterinary Microbiology 91 (2003) 23-39
9. Patel J.R., Foldi J., Bateman H., Williams J., Didlick S., and Stark R. Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges. Veterinary Microbiology 92 (2003) 1-17
10. Patel J.R., Didlick S., and Bateman H. Efficacy of a live equine herpesvirus-1 (EHV-1) strain C147 vaccine in foals with maternally derived antibody. Protection against EHV-1 infection. Equine Veterinary Journal 36 (2004) 447-451
11. Baker D.J. Rationale for the use of influenza vaccines in horses and the importance of antigenic drift. Equine Veterinary Journal 18 (1986) 93-96
12. Wilson W.D. Equine influenza. Veterinary Clinics of North America (Equine Practice) 9 (1993) 257-282
13. Paillot R., Hannant D., Kydd J.H., and Daly J.M. Vaccination against equine influenza: Quid novi?. Vaccine 24 (2006) 4047-4061
14. Mumford J.A., Jessett D.M., Hannant D., and Draper M.E. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines. Veterinary Record 12 (1994) 158-162
15. Heldens J.G.M., Kersten A.J., Weststrate M.W., and Van Den Hoven R. Duration of immunity induced by an adjuvanted and inactivated equine influenza, tetanus and equine herpesvirus 1 and 4 combination vaccine. The Veterinary Quarterly 23 (2002) 210-217
16. Heldens J.G.M., Pouwels H.G.W., and Van Loon A.A.W.M. Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95). The Veterinary Journal 167 (2004) 150-157
17. Cullinane A., Weld J., Osborne M., Nelly M., McBride C., and Walsh C. Field studies on equine influenza vaccination regimes in thoroughbred foals and yearlings. The Veterinary Journal 161 (2001) 174-185
18. Youngner J.S., Whitaker-Dowling P., Chambers T.M., Rushlow K.E., and Sebring R. Derivation and characterization of a live attenuated equine influenza vaccine virus. American Journal of Veterinary Research 62 (2001) 1290-1294
19. Drane D., and Pearse M.J. The ISCOM matrix adjuvant. In: Schijns V.E., and O'Hagan D. (Eds). Immune potentiators in modern vaccines (2006), Elsevier Academic Press, MA, USA 191-216
20. Wood J.L.N., Mumford J.A., Mair T.S., and Slater J. Boosting in equine influenza vaccination schedules: timing and time for a re-evaluation of requirements of national and international authorities. The Veterinary Journal 174 (2007) 449-450
21. Monath T.P. Prospects for the development of a vaccine against the West Nile virus. Annals of the New York Academy of Sciences 951 (2001) 1-12
22. Wetzel H., Nevill E.M., and Erasmus B.J. Studies on the transmission of African Horse Sickness. Onderstepoort Journal of Veterinary Research 37 (1970) 165-168
23. Rodriguez M., Hooghuis H., and Castano M.A. African horse sickness in Spain. Veterinary Microbiology 33 (1992) 129-142
24. Ranz A.I., Miguet J.G., Anaya C., Ventoeo A., Cortes E., Vela C., et al. Diagnostic methods for African horse sickness virus using monoclonal antibodies to structural and non-structural proteins. Veterinary Microbiology 33 (1992) 143-153
25. Craigo J.K., Steckbeck J.D., Durkin S., Howe L., Cook S.J., Issel C., et al. Discerning an effective balance between equine infectious anemia virus and vaccine efficacy. Journal of virology 79 (2005) 2666-2677
26. Patel J.R. Evaluation of a quadrivalent inactivated vaccine for the protection of cattle against diseases due to common viral infections. Journal of South African Veterinary Association 75 (2004) 137-146
27. Peters A.R., Thevasagayam S.J., Wiseman A., and Salt J.S. Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV and BRSV in experimentally infected calves. Preventive Veterinary Medicine 66 (2004) 63-77
28. Salt J.S., Thevasagayam S.J., Wiseman A., and Peters A.R. Efficacy of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV, and BRSV in experimentally infected calves. The Veterinary Journal 174 (2007) 616-626
29. Bowland S.L., and Shewen P.E. Bovine respiratory disease: commercial vaccines currently available in Canada. Canadian Veterinary Journal 41 (2000) 33-48
30. Straub O.C. Advantages and disadvantages of common vaccination programmes. In: Kaske M., Scholz H., and Höltershinken M. (Eds). Recent developments and perspectives in bovine medicine: keynote lectures of the XXII World Buiatrics Congress (2002), Klink für Rinderkrankheiten, Hannover 86-96
31. Patel J.R. Characteristics of live bovine herpesvirus-1 vaccine. The Veterinary Journal 169 (2005) 404-416
32. Alvarez M., Munoz Bielsa J., Santos L., and Makoschey B. C bovine rhinotracheitis (IBR) marker vaccine and an inactivated bovine viral diarrhoea virus (BVDV) vaccine. Vaccine 25 (2007) 6613-6617
33. Brownlie J. Bovine virus diarrhoea: pathogenesis and control. In: Kaske M., Scholz H., and Höltershinken M. (Eds). Recent developments and perspectives in bovine medicine: keynote lectures of the XXII World Buiatrics Congress (2002), Klink für Rinderkrankheiten, Hannover 24-32
34. Brownlie J., Clarke M.C., Hooper L.B., and Bell G.D. Protection of the bovine foetus from bovine virus diarrhoea virus by use of a new inactivated vaccine (Torvac-BVD). Veterinary Record 137 (1995) 58-62
35. Patel J.R., Shilleto R.W., Williams J., and Alexander D.C.S. Prevention of transplacental infection of bovine foetus by bovine viral diarrhoea virus through vaccination. Archives of Virology 147 (2002) 2453-2463
36. Salt J.S., Anthonis A.F.G., Peters A.R., Brune A., Jahnecke S., Traeder W., et al. Breite kreuzneutralisation von europäische BVDV Typ-1 und Typ-2 Stämmen und signifikante Verbesserung der Fertilität nach Testinfektionen. Tierärzlicher Praxis 32 (2004) 191-195
37. Patel J.R., and Didlick S. Efficacy of an inactivated vaccine against bovine respiratory syncytial virus in calves with maternal antibodies. American Journal of Veterinary Research 65 (2004) 417-421
38. Warzecha H., and Mason H.S. Benefits and risks of antibody and vaccine production in transgenic plants. Journal of Plant Physiology 160 (2003) 755-764
39. Rosas C.T., Kǒnig P., Beer M., Dubovi E.J., Tischer B.K., and Osterrieder N. Evaluation of the vaccine potential of an equine herpesvirus type 1 vector expressing bovine viral diarrhoea virus structural proteins. Journal of General Virology 88 (2007) 748-757
40. Schmitt J., Becher P., Theil H.-J., and Keil G.M. Expression of bovine viral diarrhoea virus glycoprotein E2 by bovine herpesvirus-1 from a synthetic ORF and incorporation of E2 into recombinant virions. Journal of General Virology 80 (1999) 2839-2848
41. Saif L.J., and Jackwood D.J. Enteric virus vaccines. In: Saif L.J., and Theil K.W. (Eds). Viral diarrhoeas of man and animals (1990), CRC Press, Boca Raton, Florida 313-329
42. Grubman M.J., and Mason P.W. Prospects, including time-frames, for improved foot and mouth disease vaccines. Scientific and Technical Review (International Office of Epizootics) 21 (2002) 589-600
43. Grubman M.J., and Baxt B. Foot-and-mouth disease. Clinical Microbiology Reviews 17 (2004) 465-493
44. Qiaohua W.U., Moraes M.P., and Grubman M.J. Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in vitro characterisation and induction of neutralising antibodies against FMDV in swine. Virus Research 93 (2003) 211-219
45. Mayr G.A., O'Donnell V., Chinsangaram J., Mason P.W., and Grubman M.J. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 19 (2001) 2152-2162
46. Plowright W. The duration of immunity in cattle following inoculation of rinderpest cell culture vaccine. Journal of Hygiene Cambridge 92 (1984) 285-296
47. Kitching R.P., Hammond J.M., and Taylor W.P. A single vaccine for the control of capripox infection in sheep and goats. Research in Veterinary Science 42 (1987) 53-60
48. Berhe G., Minet C., Goff L.E., Barrett T., Ngangnou A., Grillet C., et al. Development of a dual recombinant vaccine to protect small ruminants against peste-des-petitis-ruminants virus and capripoxvirus infection. Journal of Virology 77 (2003) 1571-1577
49. Aspden K., Passmore J.-A., Tiedt F., and Williams A.-L. Evaluation of lumpy skin disease virus, a capripox virus, as a replication-deficient vector. Journal of General Virology 84 (2003) 1985-1996
50. Kihm U., Flamand A., Pastoret P.-P., and Peterhans E. Round table on epidemiology and control of fox rabies. Veterinary Microbiology 33 (1992) 297-301
51. Pastoret P.-P., and Brochier B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. Epidemiology and Infection 116 (1998) 235-240
52. Wittmann G., and Rziha H.J. Aujeszky's disease (pseudo rabies) in pigs. In: Wittmann G. (Ed). Herpesvirus disease of cattle, horses and pigs (1989), Kluwer, Boston 230-325
53. Mettenleiter T.C. Molecular biology of pseudorabies (Aujeszky's disease) virus. Comparative Immunology and Microbiology of Infectious Diseases 14 (1991) 151-163
54. Kimman T.G., Pol J.M.A., De Wind N., Oie-Lie N., Berns A.J.M., and Gielkens A.L.J. Role of different gene in the virulence and pathogenesis of Aujeszky's disease virus. Veterinary Microbiology 33 (1992) 45-52
55. Kit S., Sheppard M., Ichmura H., and Kit M. Second-generation pseudorabies virus vaccine with deletions in thymidine kinase and glycoprotein genes. American Journal of Veterinary Research 48 (1987) 780-793
56. Marchioli C.C., Yancey R.J., Wardley R.C., Thomsen D.R., and Post L.E. A vaccine strain of pseudorabies virus with deletions in the thymidine kinase and glycoprotein X genes. American Journal of Veterinary Research 48 (1987) 1577-1583
57. Quint W.G.V., Gielkens A.L.J., Van Oirschot J.T., Berns A.J.M., and Cuypers H.T. Construction and characterisation of deletion mutants of pseudo rabies virus: a new generation of "live" vaccines. Journal of General Virology 68 (1987) 523-534
58. Pensaert M., Gielkens A.L.J., Lomniczi B., Kimman T.G., Vannier P., and Eloit M. Round table on control of Aujeszky's disease and vaccine development based on molecular biology. Veterinary Microbiology 33 (1992) 53-67
59. Van Oirschot J.T. Present and future of veterinary viral vaccinology. In: Brocchi E., and Lavaza A. (Eds). Proceedings of the 5th international congress of the European society for veterinary virology (2000), Instituto Zooprofillatico Sperimentale della Lombardia e dell Emilia Romagna, Brescia Fondazione Iniziative Zooprofilattiche e Zootechniche, Brecia, Italy 18-27
60. Kuiper A.F.C., Dazelle C.J., and Zantinga J.W. Oil adjuvanted modified live vaccine against Aujeszky's disease, based on the Bartha strain. Proceedings of 8th international pig veterinary society congress. Gent (1984) 33
61. Pensaert M.B., De Smet K., and De Waele K. Extent and duration of virulent virus excretion upon challenge of pigs vaccinated with different glycoprotein-deleted Aujeszky's disease vaccines. Veterinary Microbiology 22 (1990) 107-117
62. Chenut G., Saintilan A.-F., Burger C., Rosenthal F., Curiere C., Picard M., et al. Oral immunisation of swine with classical swine fever vaccine (Chinese strain) and transmission studies in rabbits and sheep. Veterinary Microbiology 64 (1999) 265-276
63. Kaden V., and Lange E. Vaccination as strategy of CSF control in wild boar. In: Brocchi E., and Lavaza A. (Eds). Proceedings of the 5th international congress of the European society for veterinary virology. Brecia, Italy (2000), Instituto Zooprofillatico Sperimentale della Lombardia e dell Emilia Romagna, Brescia Fondazione Iniziative Zooprofilattiche e Zootechniche 110-114
64. Lin TC, Lee RCT. An overall report on the development of a highly safe and potent lapinized hog cholera virus strain for hog cholera control in Taiwan. NSC special publication no. 5; 1981.
65. De Smit A.J., Van De Wetering G., Colijn E.C., Hulst M., Kramps J.A., Van Den Blink A., et al. The detection of antibodies against the ERNS envelope protein of classical swine fever virus. In: Brocchi E., and Lavaza A. (Eds). Proceedings of the 5th international congress of the European society for veterinary virology (2000), Instituto Zooprofillatico Sperimentale della Lombardia e dell Emilia Romagna, Brescia Fondazione Iniziative Zooprofilattiche e Zootechniche, Brescia, Italy 414-415
66. Ahrens U., Kaaden V., Drexler C., and Visser N. Efficacy of the classical swine fever (CSF) marker vaccine Porcilis Pesti in regnant sows. Veterinary Microbiology 77 (2000) 83-97
67. Bouma A., De Smit A.J., De Kluijver E.P., Terpstra C., and Moormann R.J.M. Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus. Veterinary Microbiology 66 (1999) 101-114
68. Van Gennip H.G., Van Rijn P.A., Widjojoatmodjo M.N., De Smit A.J., and Moormann R.J.N. Chimeric classical swine fever viruses containing envelope protein E (RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response. Vaccine 19 (2000) 447-459
69. Van Zijl N., Wensvoort G., De Kluijver E.P., Hulst M.M., Van Der Gulden H., Gielkens A.L.J., et al. Live attenuated pseudorabies virus expressing envelope glycoprotein E2 of hog cholera virus protects swine against both pseudorabies and hog cholera. Journal of Virology 65 (1991) 2761-2765
70. Hill H. Overview and history of mystery swine disease (swine infertility respiratory syndrome). Proceedings of the mystery swine disease committee meeting. Denver Colorado, 6 October, 1990 (1990)
71. Terpstra C., Wensvoort G., and Pol J.M.A. Experimental reproduction of porcine epidemic abortion and respiratory syndrome (mystery swine disease) by infection with Lelystad virus: Koch's postulates fulfilled. Veterinary Quarterly 13 (1991) 131-136
72. Zuckermann F.A., Alvarez Garcia E., Diaz Luque I., Christopher-Henings J., Doster A., Brito M., et al. Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge. Veterinary Microbiology 123 (2007) 69-85
73. Coggins L. African swine fever virus. Pathogenesis. Progress in Medical Virology 18 (1974) 48-63
74. Mettraux C., Ackermann M., Tratschin J.-D., and Kihm U. Approaches to the identification of non-essential genes of African swine fever virus. Veterinary Microbiology 33 (1992) 101-115
75. Kihm U., Ackerman M., Mu{combining double acute accent}ller H.K., and Pool R. Approaches to vaccination. In: Becker Y. (Ed). Developments in veterinary virology, African swine fever (1987), Martinus Nijhoff, Boston, MA 127-144
76. Van Reeth K., Van Gucht S., and Pensaert M. Investigations of the efficacy of European H1N1- and H3N2-bsased swine influenza vaccines against the novel H1N2 subtype. The Veterinary Record 153 (2003) 9-13
77. Loeffen W.L., Kamp E.M., Stockhofe-Zurwieden N., Van Nieuwstadt A.P., Bongers J.H., Hunneman W.A., et al. Survey of infectious agents involved in acute respiratory disease in finishing pigs. Veterinary Record 145 (1999) 123-129
78. Wesley R.D., Tang M., and Larger K.M. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 22 (2004) 3427-3434
79. Allan G.M., and Ellis J.A. Porcine circoviruses: a review. Journal of Veterinary Diagnostic Investigation 12 (2000) 3-14
80. Krakowa S., Ellis J.A., McNeilly F., Gilpin D., Meehan B., McCullough K., et al. Immunologic features of porcine circovirus type 2 infection. Viral Immunology 15 (2002) 567-582
81. Fenaux M., Opriessnig T., Halbur P.G., Elvinger F., and Meng X.J. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs. Journal of Virology 78 (2004) 6297-6303
82. Fan H., Ju C., Tong T., Huang H., Lv J., and Chen H. Immunogenicity of empty capsids of porcine circovirus type 2 produced in insect cells. Veterinary Research Communication 31 (2007) 487-496
83. Chunmei J., Fan H., Tan Y., Liu Z., Xi X., Cao S., et al. Immunogenicity of a recombinant pseudorabies virus expressing ORF1-ORF2 fusion protein of circovirus type 2. Veterinary Microbiology 109 (2005) 179-190
84. Wang X., Jiang W., Jiang P., Li Y., Feng Z., and Xu J. Construction and immunogenicity of recombinant adenovirus expressing the capsid protein of porcine circovirus 2 (PCV2) in mice. Vaccine 24 (2006) 3374-3380
85. Wang X., Jiang P., Li Y., Jiang W., and Dong X. Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2. Veterinary Microbiology 121 (2007) 215-224
86. Opriessnig T., McKeown N.E., Harmon K.L., Meng X.J., and Halbur P.G. Porcine circovirus type 2 infection decreases the efficacy of a modified live porcine reproductive and respiratory syndrome virus vaccine. Clinical Vaccine Immunology 13 (2006) 923-929
87. Opriesnig T., Ramamoorthy S., Madson D.M., Patterson A.R., Pal N., Carman S., et al. Differences in virulence among porcine circovirus type 2 isolates are unrelated to cluster type 2a or 2b and prior infection provides heterologous protection. Journal of general Virology 89 (2008) 2482-2491
88. Gardner I., Carpenter T.E., Leontides L., and Parsons T.D. Financial evaluation of vaccination and testing alternatives for control of parvovirus-induced reproductive failure in swine. Journal of American Veterinary Medical Association 208 (1996) 863-869
89. Elliott H. Blue tongue disease: background to the outbreak in N W Europe. The Goat Veterinary Society 23 (2007) 31-39
90. Meiswinkel R., van Run P., Leus P., and Goffredo M. Potential new Culicoides vector of bluetongue virus in northern Europe. Veterinary Record 161 (2007) 564-565
91. Erasmus B.J. In: Dinter Z., and Morein B. (Eds). Virus infections of ruminants (1990), Elsevier Science Publications 227-232
92. Menzies F.D., McCollough S.J., McKeown I.M., Forster J.L., Jess S., Batten C., et al. Evidence for transplacental and contact transmission of bluetongue virus in cattle. Veterinary Record 163 (2008) 203-209
93. Roy P. From genes to complex structures of bluetongue virus and their efficacy as vaccines. Veterinary Microbiology 33 (1992) 155-168
94. Ngichabe C.K., Wamwayi H.M., Ndungu E., Mirangi k., Bostock P.K., Black C.J., et al. Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine. Epidemiology and Infection 128 (2002) 343-349
95. Reid H.W. Epidemiology of louping-ill. In: Mayo M.A., and Harrap K.H. (Eds). Tick vectors in virus biology (1984), Academic Press, New York 161-178
96. Shaw B., and Reid H.W. Immune responses of sheep to louping-ill virus vaccine. Veterinary Record 109 (1981) 529-531
97. Dory D., Fischer T., Béven V., Cariolet R., Rziha H.-J., and Jestin A. Prime-boost immunization using DNA vaccine and recombinant Orf virus protects pigs against pseudorabies virus (Herpes suid 1). Vaccine 24 (2006) 37-39
98. Capua I., and Alexander D.J. The challenge of avian influenza to the veterinary community. Avian Pathology 35 (2006) 189-205
99. Webster R.G., Campitelli L., Krauss S., Shortridge K., Fioretti A., Guan Y., et al. Are chickens playing an increasing role in the ecology of influenza viruses?. In: Brocchi E., and Lavaza A. (Eds). Proceedings of the 5th international congress of the European society for veterinary virology (2000), Instituto Zooprofillatico Sperimentale della Lombardia e dell Emilia Romagna, Brescia Fondazione Iniziative Zooprofilattiche Zootechniche, Brescia, Italy 34-37
100. Kilbourne E.D. Future influenza vaccines and the use of genetic recombinants. Bulletin World Health Organisation 41 (1969) 643-645
101. Wood J.M., and Robertson J.S. Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza and Other Respiratory Viruses 1 (2006) 4-9
102. Swayne D.E., Lee C.W., and Spackman E. Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus. Avian Pathology 35 (2006) 141-146
103. Webster R.G., Taylor J., Pearson J., Rivera E., and Paoletti E. Immunity to Mexican H5N2 avian influenza viruses induced by a fowlpox-H5 recombinant. Avian Diseases 40 (1996) 461-465
104. Veits J., Wiesner D., Fuchs W., Hoffmann H., Mebatsion T., Mettenleiter T.C., et al. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proceedings of National Academy of Sciences 103 (2006) 8197-8202
105. Swayne D.E., Suraez D.L., Schults-Cherry S., Tumpey T.M., King D.J., Nakaya T., et al. Recombinant paramyxovirus type 1-avian influenza-H7 as a vaccine for protection of chickens against influenza and Newcastle disease. Avian Diseases 47 (2003) 1047-1050
106. Bennett R.S., LaRue R., Shaw D., Yu Q., Nagaraja K.V., Halvoroson D.A., et al. A wild goose metapneumovirus containing a large attachment glycoprotein is avirulent but protective in domestic turkeys. Journal of Virology 79 (2005) 14834-14842
107. Kapczynski D.R., and Sellers H.S. Immunization of turkeys with a DNA vaccine expressing either the F or N gene of avian Metapneumovirus. Avian Diseases 47 (2003) 1376-1383
108. Calnek B.W., Adldinger H.K., and Kahn D.E. Feather follicle epithelium: a source of enveloped and infectious cell-free herpesvirus from Marek's disease. Avian Diseases 14 (1970) 219-233
109. Beignet S.J., Smith L.P., Currie J.W., and Nair V.K. Replication kinetics of Marek disease vaccine in feathers and lymphoid tissue using PCR and virus isolation. Journal of General Virology 86 (2005) 2989-2998
110. Rispens B.H., Van Volten J., Mastenbroek N., Mass H.J.L., and Schat K.A. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI988) and its use in laboratory vaccination trials. Avian Diseases 16 (1972) 108-125
111. de Boer G.F., Groenendal J.E., Boerrigter H.M., Kok G.L., and Pol J.M. Protective efficacy of Marek's disease virus (MDV) CVI988 CEF65 clone C against challenge infection with three very virulent MDV strains. Avian Diseases 30 (1986) 276-283
112. Witter R.L. Induction of strong protection by vaccination with partially attenuated serotype 1 Marek's disease viruses. Avian Diseases 46 (2002) 925-937
113. Venugopal K. Marek's disease: an update on oncogenic mechanisms and control. Research in Veterinary Science 69 (2000) 13-17
114. Witter R.L., Calnek B.W., Buscaglia C., Gimeno I.M., and Schat K.A. Classification of Marek's disease viruses according to pathotype: philosophy and methodology. Avian Pathology 34 (2005) 75-90
115. Johnson M., Jansen E., Morrissy C., Williamson M., Ignjatovic J., Pooley C., et al. Porcine and fowl adenoviruses as cytokine delivery vectors. In: Brocchi E., and Lavaza A. (Eds). Proceedings of the 5th international congress of the European society for veterinary virology (2000), Instituto Zooprofillatico Sperimentale della Lombardia e dell Emilia Romagna, Brescia Fondazione Iniziative Zooprofilattiche e Zootechniche, Brescia, Italy 119-120
116. Mu{combining double acute accent}ller H., Schnitzler D., Bernstein F., Becht H., Cornelissen D., and Lu{combining double acute accent}tticken D.H. Infectious bursal disease of poultry: antigenic structure of the virus and control. Veterinary Microbiology 33 (1992) 175-183
117. Li S., Wang Y., and Chou C.C. Field evaluation of flock production performance of in ovo injection of infectious bursal disease virus immune complex vaccine in commercial broiler farms. Journal of Applied Poultry Research 14 (2005) 338-344
118. McNulty M.S. Chicken anemia agent: a review. Avian Pathology 20 (1991) 187-203
119. Adair B.M. Immunopathogenesis of chicken anemia virus infection. Developmental and Comparative Immunology 11 (2000) 36-42
120. Fries L.F., Tartaglia J., Kaufmann E.K., Meignier B., Paoletti E., and Plotkin S. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14 (1996) 428-434
121. Limbach K.J., and Paoletti E. Non-replicating expression vectors: applications in vaccine development and gene therapy. Epidemiology and Infection 116 (1996) 241-256
122. Stephensen C.B., Welter J., Thaker S.R., Taylor J., Tartaglia J., and Paoletti E. Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection. Journal of Virology 71 (1997) 1506-1513
123. McMillen J.K., Cochran M.D., Junker D.E., Reddy D.N., and Valencia D.M. The safe and effective use of fowlpox virus as a vector for poultry vaccines. Development Biological Standardisation 82 (1994) 137-145
124. Minke J.M., Fischer L., Baudu P.H., Guigal P.M., Sindle T., Mumford J.A., et al. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Veterinary Immunology and Immunopathology 111 (2006) 47-57
125. Mayr G.A., Chinsangaram J., and Grubman M.J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263 (1999) 496-506
126. Reddy P.S., Idamakanti N., Chen Y., Whale T., Babiuk L.A., Mehtali M., et al. Replication-defective bovine adenovirus type 3 as an expression vector. Journal of Virology 73 (1999) 9137-9144
127. Ellis R.W. New technologies for making vaccines. Vaccine 17 (1999) 1596-1604
128. Veits J., Wiesner D., Fuchs W., Hoffmann B., Granzow H., Starick E., et al. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian Influenza. Proceedings of the National Academy of Science USA 103 (2006) 8197-8202
129. Mebatsion T., Koolen M.J., de Vaan L.T., de Haas N., Braber M., Römer-Oberdörfer A., et al. Newcastle disease marker vaccine: an immunodominant eitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. Journal of Virology 76 (2002) 10138-10146
130. Moormann R.J., Van Gennip H.G., Miedema G.K., Hulst M.M., and Van Rijn P.A. Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. Virology 70 (1996) 763-770
131. Barrett A.D. Current status of flavivirus vaccines. Annals of the New York Academy of Sciences 951 (2001) 262-271
132. Palese P.P., Zheng H., Engelhardt O.K., Pleschka S., and Garcia-Sastre A. Negative RNA viruses: genetic engineering and applications. Proceedings of the National Academy of Sciences 93 (1996) 11354-11358
133. Conzelmann K.K. Genetic manipulation of non-segmented negative strand RNA viruses. Journal of General Virology 77 (1996) 381-389
134. Mebatsion T., Schnell M.J., Cox J.H., Finke S., and Conzelmann K.K. Highly stable expression of a foreign gene from rabies virus vectors. Proceedings of the National Academy of Science USA 93 (1996) 7310-7314
135. McKenna P.M., McGettiger J.P., Pommerantz R.J., Dietzschold B., and Schnell M.J. Recombinant rhabdoviruses as potential vaccines for HIV and other diseases. Current HIV Research 1 (2003) 229-237
136. Schlesinger S. Alphavirus vectors for the expression of heterologous genes. Trends in Biotechnology 11 (1993) 18-22
137. Leitner W.W., Ying H., and Restifo N.P. DNA and RNA-based vaccines; principles, progress and prospects. Vaccine 18 (2000) 765-777
138. Johnson P.A., Liu H., O'Connell T., Phelps P., Bland M., Tyczkowski J., et al. Applications in ovo technology. Poultry Science 76 (1997) 165-178
139. Freytag L.C., and Clements J.D. Bacterial toxins as mucosal adjuvants. Current Topics in Microbiology and Immunology 236 (1999) 215-236
140. Lambert P.H. New vaccines for the world-needs and prospects. The Immunologist 1 (1993) 50-55
141. Morein B.I. Veterinary Microbiology 23 (1990) 79-84
142. Bowersock T.L., and Martin S. Vaccine delivery to animals. Advances in Drug Delivery Reviews 38 (1999) 167-194
143. Frenkel H.S. La culture de la virus de la fievre aphteuse sur l'epithelium de la langue des bovides. Bulletin Office International des Epizooties 28 (1947) 155-162
144. Enders J.F., Weller T.H., and Robbins F.C. Cultivation of Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109 (1949) 85-87